Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436)

Georgina V. Long, Paolo Antonio Ascierto, Jean Jacques Grob, Omid Hamid, Richard Kefford, Celeste Lebbe, David R. Minor, Antoni Ribas, Dirk Schadendorf, Leslie Anne Fecher, Uwe Trefzer, Nikita Arya, Robert C. Gagnon, Vicki L. Goodman, Anne Siegfried, Jolly Mazumdar, Anne-Marie Martin

Research output: Contribution to journal › Meeting abstract › peer-review

Fingerprint

Dive into the research topics of 'Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436)'. Together they form a unique fingerprint.

Medicine & Life Sciences